(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethanamine

We are (1S)-1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethanamine CAS:608141-42-0 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

CAS No: 608141-42-0
Product Name: (1S)-1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethanamine
Other Name:
(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethanamine
(S)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethylamine
 
Density: 1.2±0.1 g/cm3
Boiling Point: 469.6±45.0 °C at 760 mmHg
Molecular Formula: C12H19NO4S
Molecular Weight: 273.349
Flash Point: 237.8±28.7 °C
Exact Mass: 273.103485
PSA: 87.00000
LogP: 0.65
Vapour Pressure: 0.0±1.2 mmHg at 25°C
Index of Refraction: 1.528
 
Specification
Appearance: White to off-white powder
Assay: ≥99.0%
Loss on drying: ≤0.5%
 
Application
Intermediates of Apremilast CAS: 608141-41-9.
Be used as pharmaceutical intermediate.
 
Package: 25kg/drum, can also be designed according to customer requirements.
Storage: Store in cool place. Keep container tightly closed in a dry and well-ventilated place.

(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethanamine


Related News: This leads to low numbers of one or more types of circulating blood cells, and to the need for blood transfusions. In MDS, some of the cells in the bone marrow are abnormal (dysplastic) and may have genetic abnormalities associated with them.1-terc-butil-3-propan-2-iltiourea CAS:52599-24-3 Green Valley said it would launch the drug “very soon” in China. The company also aims to roll out a phase-3 clinical trial with sites in the United States, Europe and Asia in early 2020 to facilitate global regulatory approval of the drug.4-(4-bromophenyl)-N,N-diphenylaniline CAS:202831-65-0 This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.?prop-2-yn-1-ol CAS:107-19-7 Remogliflozin is economical than other similar agents currently available in sodium glucose co-transporter-2 (SGLT2) inhibitors class, which shall help for its better access among middle and low socio-economic strata of the society, he added.Coupled with the poor global pesticide industry situation this year, the weakening of downstream customer demand has affected the sales of pesticide intermediates.

Related Products
Product Name
2-(N-Boc-N-methylamino)ethanol View Details
5-amino-1-(N-methylcarbamoyl)imidazole-4-carboxamide View Details
3,5-Difluorobenzonitrile View Details
Dicyclopentyl(dimethoxy)silane Cas:126990-35-0 manufacturer 3,4-Dichlorobenzotrifluoride manufacturer 4-Chlorobutyronitrile manufacturer (R)-1-(3,5-Bis-Trifluoromethyl-Phenyl)-Ethanol manufacturer 3-(4-Chlorobutyl)-1H-indole-5-carbonitrile manufacturer